Group 1 - The company Harbin Sanlian announced that its wholly-owned subsidiary, Harbin Longjiang Animal Health Biotechnology Co., Ltd., has changed its business scope and completed the industrial and commercial change registration [1] - The new business scope includes "Internet sales (excluding sales of goods requiring permits); food Internet sales (only selling pre-packaged food)" [1] - Other registration items remain unchanged [1]

变更后： 经营范围：许可项目：兽药生产；兽药经营；饲料添加剂生产。一般项目： 技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；农业科学研 究和试验发展；第一类医疗器械销售；第二类医疗设备租赁；第一类医疗器械生 产；非居住房地产租赁；住房租赁；消毒剂销售（不含危险化学品）；饲料原料 销售；塑料制品制造；塑料制品销售；饲料添加剂销售；食品销售（仅销售预包 装食品）；宠物食品及用品批发。互联网销售（除销售需要许可的商品）；食品互 联网销售（仅销售预包装食品）。（依法须经批准的项目，经相关部门批准后方可 开展经营活动，具体经营项目以相关部门批准文件或许可证为准） 除经营范围变更外，哈尔滨龙江动保生物科技有限公司《营业执照》的其他 登记事项均保持不变。 证券代码：002900 证券简称：哈三联 公告编号：2025-084 哈尔滨三联药业股份有限公司 关于全资子公司变更经营范围并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司收到全资子公司哈尔滨龙江动保生物科技有 限公司的通知，其对经营范围进行了变更，并已完成 ...

证券日报网讯 12月3日，哈三联在互动平台回答投资者提问时表示，公司有序推进PPAR激动剂临床工 作，目前处于临床前研究阶段。截至目前，公司暂无召开战略发布会的相关计划。 （文章来源：证券日报） ...

证券日报网讯12月1日，哈三联（002900）在互动平台回答投资者提问时表示，截至2025年11月28日， 公司股东人数为39，668户。 ...

Group 1 - The core point of the article is that Harbin Sanlian Pharmaceutical Co., Ltd. has initiated a bioequivalence trial for its Fluorobufen gel patch (40mg) in healthy subjects in China, with the trial registered under CTR20254749 and first published on November 27, 2025 [1][2] - The trial aims to compare the absorption speed and extent of the test formulation against a reference formulation under fasting conditions, assessing the bioequivalence of the two formulations [1][2] - The primary endpoints of the trial include Cmax, AUC0-t, and AUC0-∞ measured over 72 hours post-administration, while secondary endpoints include Tmax, t1/2z, λz, Ct, and AUC_%Extrap, along with monitoring adverse events and other health metrics [2] Group 2 - The current status of the trial is ongoing, and recruitment has not yet started [3]

Group 1 - Harbin Yucheng Biotechnology Co., Ltd. has been established with a registered capital of 20 million yuan [1] - The legal representative of the company is Huang Bailin [1] - The business scope includes research and development of biochemicals, biopesticides, wholesale and retail of cosmetics [1] Group 2 - The company is wholly owned by Harbin Sanlian (002900) [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002900 证券简称：哈三联 公告编号：2025-080 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第五届董事会第一次会议于2025年11月24日以 微信、电子邮件形式向全体董事发出通知。 2、本次会议于2025年11月25日以通讯表决的方式召开。 3、本次会议应出席董事9人，实际出席会议并表决的董事9人。 4、会议由半数以上董事推选秦剑飞先生主持。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有关规定。 哈尔滨三联药业股份有限公司 第五届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 二、董事会会议审议情况 会议审议并通过以下议案： 1、审议通过《关于豁免第五届董事会第一次会议提前通知的议案》 全体董事一致同意豁免本次会议提前2日通知的时限要求，同意于2025年11月25日召开第五届董事会第 一次会议。 表决情况：有效表决 ...

证券日报网讯 11月25日晚间，哈三联发布公告称，公司于2025年11月25日召开第五届董事会第一次会 议，审议通过了《关于调整组织机构的议案》。 （文章来源：证券日报） ...

（编辑 楚丽君） 证券日报网讯 11月25日晚间，哈三联发布公告称，近日，公司接到独立董事魏晶女士的通知，获悉其 已按照相关规定参加了深圳证券交易所举办的上市公司独立董事任前培训（线上），并取得由深圳证券 交易所创业企业培训中心颁发的《上市公司独立董事培训证明》。 ...

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]